Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models.

Alfaleh MA, Howard CB, Sedliarou I, Jones ML, Gudhka R, Vanegas N, Weiss J, Suurbach JH, de Bakker CJ, Milne MR, Rumballe BA, MacDiarmid JA, Brahmbhatt H, Mahler SM.

PLoS One. 2017 Oct 23;12(10):e0186137. doi: 10.1371/journal.pone.0186137. eCollection 2017.

2.

Biosimilars approved for treatment of inflammatory rheumatological diseases.

Mahler SM, Wardiana A, Jones ML, de Bakker CJ, Graham GG, Howard CB.

Int J Rheum Dis. 2016 Nov;19(11):1043-1048. doi: 10.1111/1756-185X.13037. No abstract available.

PMID:
28032957
3.

Beyond Antibodies: Development of a Novel Protein Scaffold Based on Human Chaperonin 10.

Alsultan AM, Chin DY, Howard CB, de Bakker CJ, Jones ML, Mahler SM.

Sci Rep. 2016 Nov 22;5:37348. doi: 10.1038/srep37348.

4.

Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies.

Howard CB, Fletcher N, Houston ZH, Fuchs AV, Boase NR, Simpson JD, Raftery LJ, Ruder T, Jones ML, de Bakker CJ, Mahler SM, Thurecht KJ.

Adv Healthc Mater. 2016 Aug;5(16):2055-68. doi: 10.1002/adhm.201600263. Epub 2016 Jun 10.

PMID:
27283923

Supplemental Content

Loading ...
Support Center